Chief Executive Officer and Director
John Trizzino is a U.S.-based senior executive with more than 25 years of experience advancing strategic initiatives for publicly traded biotechnology companies, primarily within the vaccine market. Prior to joining Immunovaccine, he was the Senior Vice President at Novavax Inc., where he provided strategic direction and successfully negotiated profitable joint venture and licensing agreements, including a $179M BARDA contract. Prior to joining Novavax, Mr. Trizzino held senior executive positions at MedImmune Inc., which was acquired by AstraZeneca, and ID BioMedical Inc., which is now part of GlaxoSmithKline Inc. He began his extensive career in vaccines at Henry Schein Inc. leading commercial marketing efforts and executing a series of successful commercialization and distribution agreements. Mr. Trizzino is a graduate of Long Island University and received his master’s degree in business administration from New York University’s Leonard N. Stern School of Business.
Dr. Marc Mansour
Chief Science Officer
Marc Mansour has over 12 years of experience in the biotechnology industry. He led the development of the Corporation’s unique depot based vaccine adjuvanting platform, bringing it from concept to clinical application. He oversees preclinical and clinical activities relating to the Corporation’s two clinical stage cancer vaccines including DPX-Survivac, a Survivin-based vaccine with antigens in-licensed from Merck KGaA. He also manages product development interactions in infectious diseases with commercial partners (Pfizer) and scientific collaborators at the NIH, and other institutions.
Chief Financial Officer
Ms. Kimberly Stephens is a Chartered Accountant with more than 12 years of financial management experience across several industries, including her most recent position as Director of Finance for a Canadian subsidiary of an international company, Germanischer Lloyd. Ms. Stephens gained public company experience with her role as the Director of Finance for SolutionInc, and was an Audit Manager in the Assurance and Advisory group of PricewaterhouseCoopers.
Reporting to the President & CEO, Ms. Stephens works effectively with the executive team and Board of Directors. She is responsible for producing quarterly and annual financial statements and reporting, as well as providing analysis, evaluation, and planning related to business activities, strategic alliances, and financing activities.
Vice President, Business Development
As vice president, business development, Ms. Morgan leads and facilitates Immunovaccine’s corporate alliances around the globe. She identifies research collaborations and evaluates licensing opportunities for the discovery and development of innovative vaccines.
Most recently she has worked with several small start-up companies in the life sciences sector, functioning as the Business Development lead, to license key technologies and develop corporate strategy for company positioning and growth through New Perspectives, Inc. Prior to New Perspectives, Ms Morgan held a position with Nektar Therapeutics as Director of Business Development responsible for licensing activities of Nektar’s proprietary products in gastroenterology, pain and oncology therapeutics.
Ms. Morgan is a member of the Licensing Executives Society and served on the Advisory Board of Envion International. She received her undergraduate degree in Psychology and an M.B.A. from Miami University, Oxford, Ohio.